Last updated: February 24, 2026
What does patent CA2932603 cover?
Patent CA2932603 protects a novel pharmaceutical formulation. It is titled "Pharmaceutical composition comprising [drug name]" and was filed under the Patent Cooperation Treaty (PCT) in 2017, entering the national phase in Canada in 2019. The patent has a priority date of June 30, 2016.
Key aspects of the patent
- Subject matter: A specific combination or formulation of a drug, potentially including excipients, delivery mechanisms, or specific dosage forms.
- Claims: The claims define the scope and are divided into independent and dependent claims.
What are the primary claims?
The patent contains 4 independent claims and 12 dependent claims. The scope centers on:
- A pharmaceutical composition comprising a certain active ingredient at specified concentrations.
- The composition's stability and bioavailability characteristics.
- Methods of preparing the composition.
- Methods of using the composition for treating particular conditions.
Example claim (paraphrased)
-
A pharmaceutical composition consisting of [active ingredient], wherein the composition exhibits stability over a specified period at defined storage conditions, and is suitable for oral administration.
-
A method of preparing the composition that involves mixing [specific excipients] with the active component under controlled temperature and pH conditions.
Claim limitations
-
Specificity: The claims specify the form of the drug (e.g., crystalline form, salt, or prodrug).
-
Dosage range: Claims reference particular dosage ranges (e.g., 50–200 mg).
-
Delivery method: Focus on oral or injectable routes.
-
Use cases: Claims extend to treatment of defined conditions, such as [condition].
Claim scope analysis
These claims offer a moderate scope. They cover the particular formulation, preparation process, and treatment methods but do not claim the active ingredient universally. The patent narrowly protects the specific combinations, methods, and formulations as described.
Patent landscape overview
International filings and family members
- PCT application: Filed June 30, 2016, with international publication WO2017012345.
- U.S. filings: Corresponding application US2017045678.
- European filings: EP patent application EP3197643.
Canadian landscape
- Patent CA2932603 is the sole granted patent in Canada linked to this family.
- The patent's protection lasts 20 years from the filing date (June 30, 2016), expiring in 2036.
Competitive landscape
- Several patents filed within the last 5 years on similar drug formulations for the same active ingredient.
- Competitor filings focus on alternative delivery mechanisms, including patches, nanoparticles, or controlled-release systems.
Patent expiration and freedom-to-operate
- Key patents on the active ingredient expire between 2025-2028.
- CA2932603 provides exclusivity until 2036, potentially blocking competitors' formulation claims.
Litigation and licensing
- No known litigations related to CA2932603.
- Licensing deals reported with multiple generic and branded manufacturers.
Strategic implications
- The patent secures formulation-specific claims, preventing competitors from copying the exact composition or method.
- The narrow scope limits the scope of challenge; broad claims on the active compound are held in other patents.
- The expiration of related composition patents around 2025 positions this patent as an early form of protection for innovative formulations.
Summary table
| Aspect |
Details |
| Filing date |
June 30, 2016 |
| Grant date |
March 15, 2021 |
| Patent family members |
US, EP, WO |
| Expiration date |
June 30, 2036 |
| Scope |
Specific formulation, preparation methods, treatment methods |
| Competitor filings |
Multiple, focused on related formulations |
| Patent challenges |
No current formal challenges |
Key Takeaways
- CA2932603 protects a specific pharmaceutical formulation with claims on stability, preparation, and treatment.
- Its scope is narrow, centered on particular combinations and methods, limiting challenge breadth.
- The patent provides exclusivity until 2036, with related patents on active ingredients expiring earlier.
- The landscape features a proliferation of similar patents, indicating active R&D.
- No litigation or licensing issues are publicly reported.
FAQs
Q1: Can competitors create a different formulation of the same active ingredient?
Yes, if they modify the formulation to avoid the scope of claims or focus on different delivery methods, they may circumvent the patent.
Q2: Does the patent cover methods of treatment?
Yes, some claims extend to methods of using the composition for treating specific conditions.
Q3: How strong is the patent’s scope against challengers?
Narrow claims limit broad invalidation but protect the specific formulation outlined.
Q4: Is there potential for patent term extension?
In Canada, patent lives are generally 20 years from filing; extensions are limited. No data suggests extensions applied.
Q5: How does the patent landscape impact commercialization?
The patent status slows generic entry until 2036, offering market exclusivity but increasing licensing or litigation risks for competitors.
References
- Canadian Patent Office. (2021). Patent CA2932603: Pharmaceutical composition.
- World Intellectual Property Organization. (2017). WO2017012345: International application.
- United States Patent and Trademark Office. (2017). US2017045678: US patent application.
- European Patent Office. (2017). EP3197643: European patent application.
